Purin-Ago: Non-nucleotide agonists of the P2Y11-receptor with immunosuppressant effect

Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide

agonists of the P2Y11-receptor. The agonists ensure high specificity among P2-receptors which is a key to tolerability of compounds meant for applications in longterm treatment settings. Activation of the P2Y11-receptor leads to a variety of effects in the modulation of immune system activity. For example release of immune modulatory thrombospondin-1 is induced, while lipopolysaccharide (LPS)-stimulated release of the pro-inflammatory cytokine interleukin-12 (IL- 12) is inhibited by activation of the P2Y11-receptor.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Young Corals Provide Insight into Recovery from Coral Bleaching

The number of young corals can reveal how reefs are recovering from coral bleaching. A new study from the University of Bremen, which was recently published in “PLOS ONE” journal,…

Defense or repair: How immune cells are controlled during wound healing

For the first time, scientists show a causal link between tissue repair, mitochondrial metabolism, and the activation and function of macrophages (scavenger cells) / Publication in ’Cell Metabolism’. A Cologne-based…

Transforming material topology with a drop of liquid

Liquid acts across multiple scales to reorganize connectivity in networks of artificial microscopic cells. The Science Networks of cells in nature have inspired researchers to develop their own materials made…

Partners & Sponsors